Stress, dysregulation of drug reward pathways, and the transition to drug dependence
- PMID: 17671276
- PMCID: PMC2837343
- DOI: 10.1176/appi.ajp.2007.05030503
Stress, dysregulation of drug reward pathways, and the transition to drug dependence
Abstract
This review provides a neuroadaptive perspective regarding the role of the hormonal and brain stress systems in drug addiction with a focus on the changes that occur during the transition from limited access to drugs to long-term compulsive use of drugs. A dramatic escalation in drug intake with extended access to drug self-administration is characterized by a dysregulation of brain reward pathways. Hormonal studies using an experimenter-administered cocaine binge model and an escalation self-administration model have revealed large increases in ACTH and corticosterone in rats during an acute binge with attenuation during the chronic binge stage and a reactivation of the hypothalamic-pituitary-adrenal axis during acute withdrawal. The activation of the hypothalamic-pituitary-adrenal axis with cocaine appears to depend on feed-forward activation of the mesolimbic dopamine system. At the same time, escalation in drug intake with either extended access or dependence-induction produces an activation of the brain stress system's corticotropin-releasing factor outside of the hypothalamus in the extended amygdala, which is particularly evident during acute withdrawal. A model of the role of different levels of hormonal/brain stress activation in addiction is presented that has heuristic value for understanding individual vulnerability to drug dependence and novel treatments for the disorder.
Figures
![FIGURE 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f1.gif)
![FIGURE 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f2.gif)
![FIGURE 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f3.gif)
![FIGURE 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f4.gif)
![FIGURE 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f5.gif)
![FIGURE 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f6.gif)
![FIGURE 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2837343/bin/nihms140596f7.gif)
Similar articles
-
Corticotropin-Releasing Factor (CRF) and Addictive Behaviors.Int Rev Neurobiol. 2017;136:5-51. doi: 10.1016/bs.irn.2017.06.004. Epub 2017 Aug 7. Int Rev Neurobiol. 2017. PMID: 29056155 Free PMC article. Review.
-
Addiction as a stress surfeit disorder.Neuropharmacology. 2014 Jan;76 Pt B(0 0):370-82. doi: 10.1016/j.neuropharm.2013.05.024. Epub 2013 Jun 6. Neuropharmacology. 2014. PMID: 23747571 Free PMC article. Review.
-
Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal.Brain Res. 2003 Feb 28;964(2):187-99. doi: 10.1016/s0006-8993(02)03929-x. Brain Res. 2003. PMID: 12576179
-
Drug addiction, dysregulation of reward, and allostasis.Neuropsychopharmacology. 2001 Feb;24(2):97-129. doi: 10.1016/S0893-133X(00)00195-0. Neuropsychopharmacology. 2001. PMID: 11120394 Review.
-
Neurobiology of stress and cocaine addiction. Studies on corticotropin-releasing factor in rats, monkeys, and humans.Ann N Y Acad Sci. 1998 Jun 30;851:371-87. doi: 10.1111/j.1749-6632.1998.tb09011.x. Ann N Y Acad Sci. 1998. PMID: 9668628 Review.
Cited by
-
Co-targeting the kappa opioid receptor and dopamine transporter reduces motivation to self-administer cocaine and partially reverses dopamine system dysregulation.Sci Rep. 2024 Mar 18;14(1):6509. doi: 10.1038/s41598-024-53463-9. Sci Rep. 2024. PMID: 38499566 Free PMC article.
-
Failure to mate enhances investment in behaviors that may promote mating reward and impairs the ability to cope with stressors via a subpopulation of Neuropeptide F receptor neurons.PLoS Genet. 2024 Jan 18;20(1):e1011054. doi: 10.1371/journal.pgen.1011054. eCollection 2024 Jan. PLoS Genet. 2024. PMID: 38236837 Free PMC article.
-
Does Morphine Exposure Before Gestation Change Anxiety-Like Behavior During Morphine Dependence in Male Wistar Rats?Addict Health. 2023 Jul;15(3):169-176. doi: 10.34172/ahj.2023.1396. Epub 2023 Jul 29. Addict Health. 2023. PMID: 38026722 Free PMC article.
-
The effects of sleep restriction during abstinence on oxycodone seeking: Sex-dependent moderating effects of behavioral and hypothalamic-pituitary-adrenal axis-related phenotypes.Physiol Behav. 2023 Dec 1;272:114372. doi: 10.1016/j.physbeh.2023.114372. Epub 2023 Oct 5. Physiol Behav. 2023. PMID: 37805135
-
Chronic administration of a norepinephrine antagonist prevents and partially reverses escalation of cocaine self-administration.Addict Biol. 2023 Sep;28(9):e13316. doi: 10.1111/adb.13316. Addict Biol. 2023. PMID: 37644893
References
-
- Koob GF. Allostatic view of motivation: implications for psychopathology. In: Bevins RA, Bardo MT, editors. Motivational Factors in the Etiology of Drug Abuse (series title: Nebraska Symposium on Motivation, vol 50); Lincoln, Neb: University of Nebraska Press; 2004. pp. 1–18. - PubMed
-
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
-
- Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science. 1997;278:52–58. - PubMed
-
- Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118:304–309. - PubMed
-
- Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 1998;51:23–47. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P50 AA006420/AA/NIAAA NIH HHS/United States
- MH076537/MH/NIMH NIH HHS/United States
- AA06420/AA/NIAAA NIH HHS/United States
- R01 MH076537/MH/NIMH NIH HHS/United States
- K05 DA000049/DA/NIDA NIH HHS/United States
- DK26741/DK/NIDDK NIH HHS/United States
- P60 DA005130/DA/NIDA NIH HHS/United States
- P01 DK026741-280004/DK/NIDDK NIH HHS/United States
- R01 DA004043-21/DA/NIDA NIH HHS/United States
- R37 AA008459/AA/NIAAA NIH HHS/United States
- DA04398/DA/NIDA NIH HHS/United States
- P50 DA005130/DA/NIDA NIH HHS/United States
- AA08459/AA/NIAAA NIH HHS/United States
- RR024143/RR/NCRR NIH HHS/United States
- UL1 RR024143/RR/NCRR NIH HHS/United States
- R01 AA008459/AA/NIAAA NIH HHS/United States
- P01 DK026741/DK/NIDDK NIH HHS/United States
- DA05130/DA/NIDA NIH HHS/United States
- P60 AA006420-23/AA/NIAAA NIH HHS/United States
- R01 AA008459-17/AA/NIAAA NIH HHS/United States
- P60 AA006420/AA/NIAAA NIH HHS/United States
- DA04043/DA/NIDA NIH HHS/United States
- DA00049/DA/NIDA NIH HHS/United States
- R01 DA004043/DA/NIDA NIH HHS/United States
- R01 DA004398-20/DA/NIDA NIH HHS/United States
- R01 DA004398/DA/NIDA NIH HHS/United States